Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“90% of druggable targets still lack small molecules. To solve this issue a paper published in Science Magazine. Deep contrastive learning enables genome-wide virtual screening – attempts to address this.
DrugCLIP: contrastive learning for protein–ligand matching at AlphaFold2 scale.
10M× faster than docking. Wet-lab validated.
500M×10K screen = a new era in drug discovery?”
Title: Deep contrastive learning enables genome-wide virtual screening
Authors: Yinjun Jia, Bowen Gao, Jiaxin Tan, Jiqing Zheng, Xin Hong, Wenyu Zhu, Haichuan Tan, Yuan Xiao, Liping Tan, Hongyi Cai, Yanwen Huang, Zhiheng Deng, Xiangwei Wu, Yue Jin, Yafei Yuan, Jiekang Tian, Wei He, Weiying Ma, Yaqin Zhang, Lei Liu, Chuangye Yan, Wei Zhang, Yanyan Lan
Read the Full Article.
More posts featuring Vivek Subbiah.